
    
      To assess the non-hematologic toxicity and determine the phase 2 dose of gemcitabine in
      combination with vinorelbine followed by carmustine, etoposide and cyclophosphamide and
      autologous hematopoietic stem cell transplantation [aka peripheral blood stem cell (PBSC)].
    
  